SC 13G 1 dsc13g.htm SCHEDULE 13G Schedule 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(RULE 13D-102)

 

Information Statement Pursuant to Rules 13d-1 and 13d-2

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

OSI PHARMACEUTICALS, INC.

(NAME OF ISSUER)

 

Common, $.01 par value per share

(Title of Class of Securities)

 

671040 103

(CUSIP Number)

 

October 21, 2005

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

 

¨ Rule 13d-1(b)

 

x Rule 13d-1(c)

 

¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 671040 103

    13G    Page 2 of 6 Pages

 

  1.  

NAME OF REPORTING PERSONS.

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

 

            BROOKSIDE CAPITAL PARTNERS FUND, L.P.

            EIN NO.: 04-3313066

    
  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(A)  ¨

(B)  ¨

    
  3.  

SEC USE ONLY

 

 

 

    
  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

            UNITED STATES OF AMERICA

    

 

NUMBER OF  

SHARES  

BENEFICIALLY  

OWNED BY  

EACH  

REPORTING  

PERSON  

WITH  

 

  

  5.    SOLE VOTING POWER

 

2,642,500

 

  6.    SHARED VOTING POWER

 

0

 

  7.    SOLE DISPOSITIVE POWER

 

2,642,500

 

  8.    SHARED DISPOSITIVE POWER

 

0

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

            2,642,500

    
10.  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

¨

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

            5.1%

    
12.  

TYPE OF REPORTING PERSON*

 

 

            PN

    

 

 

 

Item 1(a). Name of Issuer

 

The name of the issuer to which this filing on Schedule 13G relates is OSI Pharmaceuticals, Inc. (the “Company”).

 

Item 1(b). Address of Issuer’s Principal Executive Offices

 

The principal executive offices of the Company are located at 58 South Service Road, Suite 110, Melville, NY 11747.

 

Item 2(a). Name of Person Filing

 

This Statement is being filed on behalf of Brookside Capital Partners Fund, L.P., a Delaware limited partnership (the “Brookside Fund”). Brookside Capital Investors, L.P., a Delaware limited partnership (“Brookside Investors”) is the sole general partner of Brookside Fund. Brookside Capital Management, LLC, a Delaware limited liability company (“Brookside Management”) is the sole general partner of Brookside Investors. Mr. Domenic J. Ferrante is the sole managing member of Brookside Management.

 

Item 2(b). Address of Principal Business Office or, if none, Residence

 

The principal business address of each of the Brookside Fund, Brookside Investors, Brookside Management and Mr. Ferrante is 111 Huntington Avenue, Boston, Massachusetts 02199.

 

Item 2(c). Citizenship

 

Each of the Brookside Fund, Brookside Investors and Brookside Management is organized under the laws of the State of Delaware. Mr. Ferrante is a citizen of the United States.

 

Item 2(d). Title of Class of Securities

 

The class of equity securities of the Company to which this filing on Schedule 13G relates is Common Stock, Par Value $.01 per share (“Common Stock”).

 

Item 2(e). CUSIP Number

 

The CUSIP number of the Company’s Common Stock is 671040 103.

 

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.

 

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) ¨ An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
(f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
(g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
(h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

x If this statement is filed pursuant to §240.13d-1(c), check this box.

 

Item 4. Ownership

 

Item 4(a). Amount beneficially owned

 

As of the close of business on October 21, 2005, the Brookside Fund owned 2,642,500 shares of Common Stock of the Company. The Brookside Fund acts by and through its general partner, Brookside Investors. Brookside Investors acts by and through its general partner, Brookside Management. Mr. Domenic J. Ferrante is the managing member of Brookside Management and thus is the controlling person of Brookside Management. No person other than the respective owner referred to herein of shares of Common Stock is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of such shares of Common Stock.

 

Item 4(b). Percent of Class

 

As of the close of business on October 21, 2005, the Brookside Fund was the beneficial owner of 5.1% of the Common Stock of the Company. The aggregate percentage of Common Stock reported owned by the Brookside Fund is based upon 51,438,670 shares of Common Stock outstanding, which is the total number of shares of Common Stock outstanding as of September 26, 2005, based on representations made in the Company’s Amendment No. 1 to Form S-4 filed with the Securities and Exchange Commission on October 6, 2005.

 

Item 4(c). Number of shares as to which such person has:

 

sole power to vote or to direct the vote:    2,642,500
   

(i)

   

shared power to vote or to direct the vote:

    0
   

(ii)

   

sole power to dispose or to direct the disposition of:

    2,642,500
   

(iii)

   

shared power to dispose or to direct the disposition of:

    0

 

 

 

 

Item 5. Ownership of Five Percent or Less of a Class

 

Not Applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group

 

Not Applicable.

Item 10. Certification

 

By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

Dated: October 31, 2005

 

BROOKSIDE CAPITAL PARTNERS FUND, L.P.

 

By: /s/ Domenic J. Ferrante                        

        Name: Domenic J. Ferrante

        Title: Managing Director